Mechanistic investigations into interactions between IGF-I and IGFBPs and their impact on facilitating cell migration on vitronectin

Growth Factors

Volumn 28, Issue 5, 2010, Pages 359-369

  Kricker, Jennifer A ^a   Hyde, Carolyn E ^a   Van Lonkhuyzen, Derek R ^a   Hollier, Brett G ^a   Shooter, Gary K ^a   Leavesley, David I ^a   Herington, Adrian C ^a   Upton, Zee ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Cell migration; Heparin binding; IGF I; IGFBP; Vitronectin

Indexed keywords

COLLAGEN TYPE 4; FIBRONECTIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; VITRONECTIN;

ARTICLE; BINDING ASSAY; CELL ACTIVITY; CELL CULTURE; CELL MIGRATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNODETECTION; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION;

CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN TYPE IV; FIBRONECTINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; PROTEIN INTERACTION DOMAINS AND MOTIFS; VITRONECTIN;

EID: 77957768371     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2010.494603     Document Type: Article

References (50)

1. Abrass CK, Berfield AK, Andress DL. 1997. Heparin binding domain ofinsulin-like growth factor binding protein-5 stimulates mesangial cell migration. Am J Physiol 273(6 Pt 2):F899-F906.
2. Ainscough SL, Barnard Z, Upton Z, Harkin DG. 2006. Vitronectin supports migratory responses of corneal epithelial cells to substrate bound IGF-I and HGF, and facilitates serum-free cultivation. Exp Eye Res 83(6):1505-1514.
3. Arai T, Busby W, Jr., Clemmons DR. 1996. Binding ofinsulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 137(11):4571-4575.
4. Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, Maack C, Linhardt RJ, Bar K, Caldwell EE, Weiler J, Bar RS. 1995. IGFBP-3 and IGFBP-5 association with endothelial cells: Role of C-terminal heparin binding domain. Growth Regul 5(1): 1-17.
5. Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA. 1997. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest 99(6):1390-1398.
6. Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA, Mc Intosh J, Mc Caig C, Winters ZE, Perks CM. 2006. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 147(7): 3484-3500.
7. Camacho-Hubner C, Busby WH, Jr., Mc Cusker RH, Wright G, Clemmons DR. 1992. Identification of the forms ofinsulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J Biol Chem 267(17):11949-11956.
8. Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR. 1998. Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3. Am J Physiol 275(2 Pt 1):E321-E331.
9. Clemmons DR, Maile LA. 2005. Interaction between insulin-like growth factor-I receptor and alphaVbeta3 integrin linked signaling pathways: Cellular responses to changes in multiple signaling inputs. Mol Endocrinol 19(1):1-11.
10. Dawson RA, Upton Z, Malda J, Harkin DG. 2006. Preparation of cultured skin for transplantation using insulin-like growth factor I in conjunction with insulin-like growth factor binding protein 5, epidermal growth factor, and vitronectin. Transplantation 81(12):1668-1676.
11. Doerr ME, Jones JI. 1996. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 271(5): 2443-2447.
12. Eliceiri BP. 2001. Integrin and growth factor receptor crosstalk. Circ Res 89(12):1104-1110.
13. Fu P, Thompson JA, Bach LA. 2007. Promotion of cancer cell migration: An insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. J Biol Chem 282(31): 22298-22306.
14. Giancotti FG, Ruoslahti E. 1999. Integrin signaling. Science 285(5430):1028-1032.
15. Gockerman A, Prevette T, Jones JI, Clemmons DR. 1995. Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology 136(10):4168-4173.
16. Gui Y, Murphy LJ. 2001. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): Demonstration ofIGF-I/IGFBP-3/fn ternary complexes in human plasma. J Clin Endocrinol Metab 86(5):2104-2110.
17. Hamilton GS, Lysiak JJ, Han VK, Lala PK. 1998. Autocrine-paracrine regulation of human trophoblast invasiveness by insulin-like growth factor (IGF)-II and IGF-binding protein (IGFBP)-1. Exp Cell Res 244(1):147-156.
18. Hollier B, Harkin DG, Leavesley D, Upton Z. 2005. Responses of keratinocytes to substrate-bound vitronectin: Growth factor complexes. Exp Cell Res 305(1):221-232.
19. Hollier BG, Kricker JA, Van Lonkhuyzen DR, Leavesley DI, Upton Z. 2008. Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-Kinase/AKT pathway by alphav-integrins and the IGF-I receptor. Endocrinology 149(3):1075-1090.
20. Hsieh T, Gordon RE, Clemmons DR, Busby WH, Jr., Duan C. 2003. Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins. J Biol Chem 278(44):42886-42892.
21. Hyde C, Hollier B, Anderson A, Harkin D, Upton Z. 2004. Insulin-like growth factors (IGF) and IGF-binding proteins bound to vitronectin enhance keratinocyte protein synthesis and migration. J Invest Dermatol 122(5):1198-1206.
22. Jones JI, Gockerman A, Busby WH, Jr., Camacho-Hubner C, Clemmons DR. 1993a. Extracellular matrix contains insulin-like growth factor binding protein-5: Potentiation of the effects of IGF-I. J Cell Biol 121(3):679-687.
23. Jones JI, Gockerman A, Busby WH, Jr., Wright G, Clemmons DR. 1993b. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 90(22): 10553-10557.
24. Koivisto L, Larjava K, Hakkinen L, Uitto VJ, Heino J, Larjava H. 1999. Different integrins mediate cell spreading, haptotaxis and lateral migration of HaCaT keratinocytes on fibronectin. Cell Adhes Commun 7(3):245-257.
25. Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z. 2003. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins withvitronectin. Endocrinology 144(7):2807-2815.
26. Labat-Robert J, Bihari-Varga M, Robert L. 1990. Extracellular matrix. FEBS Lett 268(2):386-393.
27. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head ofbacteriophage T4. Nature 227(5259): 680-685.
28. Larsen M, Artym VV, Green JA, Yamada KM. 2006. The matrix reorganized: Extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 18(5):463-471.
29. Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA. 1993. Integrin beta 1-and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 121(1):163-170.
30. Le Roith D, Roberts CT, Jr. 2003. The insulin-like growth factor system and cancer. Cancer Lett 195(2):127-137.
31. Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clarke J, Clemmons DR. 2006a. Insulin-like growth factor-I signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184 sequence of the beta3-subunit ofalphaVbeta3. Mol Endocrinol 20(2):405-413.
32. Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clarke J, Ling Y, Clemmons DR. 2006b. The heparin binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling. Mol Endocrinol 20(4):881-892.
33. Martin JA, Buckwalter JA. 2000. The role of chondrocyte-matrix interactions in maintaining and repairing articular cartilage. Biorheology 37(1-2):129-140.
34. Martin JL, Jambazov S. 2006. Insulin-like growth factor binding protein-3 in extracellular matrix stimulates adhesion of breast epithelial cells and activation of p44/42 mitogen-activated protein kinase. Endocrinology 147(9):4400-4409.
35. Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Durr P, Klocker H. 2009. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: Inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer 16(3):795-808.
36. Nam T Moralez A, Clemmons D. 2002. Vitronectin binding to IGF binding protein-5 (IGFBP-5) alters IGFBP-5 modulation of IGF-I actions. Endocrinology 143(1):30-36.
37. Nathan C, Sporn M. 1991. Cytokines incontext. J Cell Biol 113(5): 981-986.
38. Noble A, Towne C, Chopin L, Leavesley D, Upton Z. 2003. Insulin-like growth factor-II bound to vitronectin enhances MCF-7 breast cancer cell migration. Endocrinology 144(6): 2417-2424.
39. Parker A, Clarke JB, Busby WH, Jr., Clemmons DR. 1996. Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5. J Biol Chem 271(23):13523-13529.
40. Parker A, Rees C, Clarke J, Busby WH, Jr., Clemmons DR. 1998. Binding ofinsulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I. Mol Biol Cell 9(9): 2383-2392.
41. Richards S, Leavesley D, Topping G, Upton Z. 2008. Development of defined media for the serum-free expansion of primary keratinocytes and human embryonic stem cells. Tissue Eng Part C Methods 14(3):221-232.
42. Ruoslahti E. 1989. Proteoglycans in cell regulation. J Biol Chem 264(23):13369-13372.
43. Samani AA, Yakar S, Le Roith D, Brodt P. 2007. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28(1):20-47.
44. Schleicher I, Parker A, Leavesley D, Crawford R, Upton Z, Xiao Y 2005. Surface modification by complexes of vitronectin and growth factors for serum-free culture of human osteoblasts. Tissue Eng 11(11-12):1688-1698.
45. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW. 2004. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32(3):859-868.
46. Tissue Therapies Ltd. 2009. ASX Announcement: Excellent VitroGro® Results: Australian Human Trial. Available from http://www.tissuetherapies.com/ investors/091123%20TIS %20ASX%20Aust%20Results%20Final.pdf
47. Towbin H, Staehelin T, Gordon J. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76(9):4350-4354.
48. Upton Z, Cuttle L, Noble A, Kempf M, Topping G, Malda J, Xie Y Mill J, Harkin DG, Kravchuk O, Leavesley DI, Kimble RM. 2008. Vitronectin: Growth factor complexes hold potential as a wound therapy approach. J Invest Dermatol 128(6):1535-1544.
49. Upton Z, Webb H, Hale K, Yandell CA, Mc Murtry JP, Francis GL, Ballard FJ. 1999. Identification of vitronectin as a novel insulin-like growth factor-II binding protein. Endocrinology 140(6):2928-2931.
50. Wang GK, Hu L, Fuller GN, Zhang W. 2006. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 281(20):14085-14091.